Oral etoposide for treatment and/or maintenance treatment of recurrent epithelial ovarian cancer
نویسندگان
چکیده
منابع مشابه
Treatment of recurrent epithelial ovarian cancer
Epidemiologic analysis reveals that the mortality rate from ovarian cancer is continuously decreasing due to the improvement of surgery and chemotherapy. However, the prognosis of ovarian cancer patients is still unsatisfactory overall considering that only 30% of patients are alive after five years. In fact, although surgery and first-line systemic chemotherapy induces complete and partial res...
متن کاملWeekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.
BACKGROUND Response rates to chemotherapy in relapsed, platinum resistant epithelial ovarian cancer remain poor. We have explored the effectiveness of weekly cisplatin combined with prolonged oral etoposide in this patient group. PATIENTS AND METHODS Forty-two women with relapsed, advanced ovarian cancer were treated with cisplatin 60 mg/m2 on days 1, 8, 15, 29, 36 and 43 and oral etoposide 5...
متن کاملTCRM-4317-Treatment of recurrent epithelial ovarian cancer
Correspondence: Sandro Pignata Divisione di Oncologia Medica, Dipartimento Uro-Ginecologico, istituto Nazionale Tumori, via M. Semmola, 80131 – Napoli – italy Tel +39 81 590 3637 Fax +39 81 590 3861 email [email protected] Abstract: Epidemiologic analysis reveals that the mortality rate from ovarian cancer is continuously decreasing due to the improvement of surgery and chemot...
متن کاملTreatment of recurrent ovarian cancer.
Recurrent ovarian cancer is a common clinical problem and the management of each patient must be individualized. Diagnosis is usually based on a progressively rising CA-125 titre, and a CT scan of the pelvis and abdomen, together with a chest X-ray should be performed in this situation. Although there is no study to support immediate treatment in the asymptomatic patient, our approach is to com...
متن کاملLONG TERM ORAL ETOPOSIDE AS SECOND-LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY
Background: The activity and toxicity of etoposide in women with recurrent ovarian cancer was evaluated in a case series of women with recurrent ovarian cancer who had measurable disease, Methods: All patients had plior platinum-based chemotherapy and developed progressive disease, Etoposide was given as 50mg/day for 21 days every 4 weeks until progression of disease or prohibitive toxicit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2020
ISSN: 1465-1858
DOI: 10.1002/14651858.cd013537